Inclusion Criteria:

          -  Patients with AML or biphenotypic or bilineage leukemia (including a myeloid
             component) who have failed prior therapy. Patients with isolated extramedullary AML
             are eligible. The World Health Organization (WHO) classification will be used for AML

          -  Elderly (> 60 years old) patients with newly diagnosed AML not eligible for intensive
             chemotherapy are also eligible

          -  AML patients with prior history of myelodysplastic syndrome (MDS) or chronic
             myelomonocytic leukemia (CMML) regardless of prior therapy received, are eligible at
             the time of diagnosis of AML

          -  Subjects must have documented IDH2 gene mutation

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 3

          -  Adequate renal function including creatinine < 2 unless related to the disease

          -  Total bilirubin < 2 x upper limit of normal (ULN) unless increase is due to Gilbert's
             disease or leukemic involvement

          -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < 3 x ULN
             unless considered due to leukemic involvement

          -  Provision of written informed consent

          -  Oral hydroxyurea and/or cytarabine (up to 2 g/m2) for patients with rapidly
             proliferative disease is allowed before the start of study therapy, as needed, for
             clinical benefit and after discussion with the principal investigator (PI). Concurrent
             therapy for central nervous system (CNS) prophylaxis or continuation of therapy for
             controlled CNS disease is permitted

          -  Females must be surgically or biologically sterile or postmenopausal (amenorrheic for
             at least 12 months) or if of childbearing potential, must have a negative serum or
             urine pregnancy test within 72 hours before the start of the treatment

          -  Women of childbearing potential must agree to use an adequate method of contraception
             during the study and until 3 months after the last treatment. Males must be surgically
             or biologically sterile or agree to use an adequate method of contraception during the
             study until 3 months after the last treatment

        Exclusion Criteria:

          -  Patients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia
             (French-American-British [FAB] class M3-AML)

          -  Active and uncontrolled comorbidities including active uncontrolled infection,
             uncontrolled hypertension despite adequate medical therapy, active and uncontrolled
             congestive heart failure New York Heart Association (NYHA) class III/IV, clinically
             significant and uncontrolled arrhythmia as judged by the treating physician

          -  Any other medical, psychological, or social condition that may interfere with study
             participation or compliance, or compromise patient safety in the opinion of the
             investigator

          -  Pregnant or breastfeeding